Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.38 |
| ▸ | USP8 | P40818 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | BRD1 | O95696 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348323 | 0.81 | BRD4 (0.66) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30054124 | 0.81 | BRD4 (0.66) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30053050 | 0.78 | GUSB (0.49) | BRD4GUSBCYP1A1CYP1B1PARP1 | |
| SCHEMBL348402 | 0.78 | GUSB (0.49) | BRD4GUSBCYP1A1CYP1B1PARP1 | |
| SCHEMBL147454 | 0.76 | BRD4 (0.56) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL147189 | 0.74 | BRD4 (0.48) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL375638 | 0.74 | KDM4E (0.46) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL377887 | 0.73 | KDM4E (0.47) | BRD4GUSBPARP1 | |
| SCHEMBL10237910 | 0.73 | KDM4E (0.47) | CYP1A1CYP1B1 | |
| SCHEMBL31115538 | 0.73 | PDE7A (0.48) | BRD4USP8PARP1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | claimed |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP (CA) | 2016-12-01 | — | — | US | claimed |
| EP-3035933-A2 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | Resverlogix Corporation (CA) | 2016-06-29 | — | — | EP | claimed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | claimed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | claimed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | claimed |
| WO-2015025228-A2 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP. (CA) | 2015-02-26 | — | — | WO | claimed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | claimed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | BRD4 744/4885HDAC3 1263/4885HDAC4 981/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885HDAC3 54/4885HDAC4 84/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | BRD4 1/4885HDAC3 109/4885HDAC4 180/4885 |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | PCSK9, TGFB1, HMGCR | BRD4 3081/4885HDAC3 135/4885HDAC4 71/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885HDAC3 467/4885HDAC4 833/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | BRD4 693/4885HDAC3 869/4885HDAC4 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.